Articles

Researchers have found that giving patients a dual therapy of bimatoprost and a beta-blocker is an effective method of lowering intraocular blood pressure (IOP) in patients with open-angle glaucoma.

The Pediatric Cataract Initiative has set a deadline of 15 November for the receipt of applications for its inaugural single small research grant.

Allergan has been given FDA approval for its drug Ozurdex (dexamethasone intravitreal implant) 0.7 mg for the treatment of non-infectious ocular inflammation.

ISTA Pharmaceuticals has highlighted results from its Phase 2 clinical study on Remura dry eye solution.

ISTA Pharmaceuticals has highlighted results from its Phase 2 clinical study on Remura dry eye solution.

Acucela and Otsuka Pharmaceutical have entered into a definitive agreement for the joint development and promotion of OPA-656, an adenosine A2a receptor agonist under development for treating glaucoma.

Investigators from The Scripps Research Institute, and Thomas Reh, PhD from the University of Washington, received the highest possible scores for their proposal to investigate the regenerative potential of retinal cells, resulting in a $4.66 million NIH Transformative Award.

AstraZeneca and UCL Institute of Ophthalmology are collaborating to develop regenerative medicines for diabetic retinopathy (DR).

opcon has launched the LENTIS Mplustoric intraocular lens (IOL.

Applied Genetics Technology Corporation (AGTC) has received a grant from the FDA (FDA Orphan Drugs Programme) to fund a Phase II Human Clinical Trial evaluating the safety and efficacy of a treatment for Leber congenital amaurosis (LCA), a genetic retinal disease.

A clinical trial is being conducted by the Cornea and Laser Eye Institute (CLEI) into the efficacy and safety of corneal collagen crosslinking (CXL) using riboflavin/dextran and hypotonic riboflavin in patients with progressive keratoconus and corneal ectasia.

Collaborative research has led to the development of an adaptive optics-optical coherence tomography (AO-OCT) system that allows ophthalmologists to see the eye's retina at the individual level.

Ophthalmic blogger, Irv Arons writes a tell all on what stem cells are all about, who's involved, who they are collaborating with, what type of stem cells they are using and what diseases they are aimed at.

A stem cell treatment to replace diseased parts of the retina is being pioneered by scientists funded by the Medical Research Council, the Macular Vision Research Foundation and Fight for Sight.

Results from research performed by St Jude Children's Research Hospital has demonstrated vision lost as a result of glaucoma, diabetic retinopathy and age-related macular degeneration (AMD) may be restored.

In a recent study published in the Archives of Ophthalmology researchers found that the recurrence of epithelial keratitis, stromal keratitis, conjunctivitis and blepharitis as a result of ocular herpes simplex virus (HSV) was decreased.

Findings from Retina Implant AG's first human clinical trial of subretinal electronic implants have revealed that useful vision can be restored and a significant cost-benefit to the patient's quality of life gained.

A polymer-based corneal prosthesis has been developed by the Fraunhofer Institute for Applied Polymer Research (IAP), Postdam-Golm, as part of the EU's Artificial Cornea project.

Avedro and Emery University have entered into an agreement to combine clinical trial data for corneal collagen cross-linking.

Scientists from around the world gathered at a recent Glaucoma Research Foundation Catalyst meeting to discuss new research ideas that could lead to a cure for glaucoma.

Collaborative research, led by King?s College in London has led to the identification of a gene associated with myopia and glaucoma.

A new product, MigraLens, designed to filter red and blue light and help migraine sufferers is now available in the UK in a range of branded plano eyewear including fit-overs for presciption glasses.

A team of retina specialists at the Doheny Eye Institute, University of Southern California, led by Srinivas Sadda, MD, conducting a study using have found that 76% of eyes in patients with AMD had peripheral abnormalities.

The Paediatric Cataract Initiative is now accepting applicants for its inaugural single small research grant.

A Phase 2a clinical study has been initiated for Promedior's anti-fibrotic therapeutic, PRM-151, to evaluate its efficacy, safety and tolerability.

Lions Clubs International Foundation (LCIF) has appointed Dr Wing-Kun Tam to the global advisory council of the Paediatric Cataract Initiative

Bausch + Lomb has concluded its acquisition of a portion of the assets and intellectual property for Miochol(R)-E from affiliates of Novartis AG. The business intends to complete the acquisition of the remaining assets and intellectual property upon the necessary regulatory clearance.

The WaveLight Refractive Suite from Alcon is now available to European doctors.

Scientists at the University of Southampton have developed biodegradable polymer microspheres which may have the ability to deliver stem cells to damaged retina photoreceptor cells to help with their repair.

The WaveLight Refractive Suite from Alcon is now available to European doctors. The news came during the 2010 European Society of Cataract and Refractive Surgeons (ESCRS) annual meeting in Paris, France.